Articles published by Almirall S.A.

Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
From Almirall S.A.
Via Business Wire
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
From Almirall S.A.
Via Business Wire
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
From Almirall S.A.
Via Business Wire
Tickers ABSI
Almirall’s Nine-month 2023 Results:
From Almirall S.A.
Via Business Wire
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
From Almirall S.A.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.